Innovative laser system

Article

Schwind product profile.

SCHWIND has announced the addition of the new flagship system to the company's excimer laser portfolio, the SCHWIND AMARIS 1050RS.

This innovative laser system operates at a repetition rate of 1050 Hz, which enables an extremely short ablation time of just 1.3 seconds per dioptre (myopia, without astigmatism, 12.5 mm vertex distance and 6 mm optical zone). According to the company, this leads to greater safety and patient comfort.

Additionally, it is reported that this system shortens the length of exposure time for the corneal stroma, minimizing the risk of drying out. Also, the length of time that the patient is required to fixate on the green light is reduced. Further to this, the new system incorporates Intelligent Thermal Effect Control that protects the tissue from thermal damage.

The company states that another innovative feature of AMARIS 1050RS is the active 7 D eye tracking in space and time. This Latency-Free Tracking enables anticipation and pre-compensation of eye movements during the period between acquisition of the eyetracker image and triggering of the subsequent laser pulses - resulting in zero latency and greater safety.

Company name: SCHWIND eye-tech-solutions GmbH & Co. KG
Telephone: +49 (0) 60 27/5 08-164
E-mail: antje.splittdorf@eye-tech.netWebsite: www.eye-tech-solutions.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.